ClinicalTrials.gg
Drug

Cemiplimab clinical trials

Also written Libtayo and REGN2810.

studies test it
135
open now
68
in phase 3
11
first study started
2010

How each study uses cemiplimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the cemiplimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
28 Sept 2018 · LIBTAYO · BLA 761097 (FDA, Drugs@FDA)
European Union
28 Jun 2019 · Libtayo · EMEA/H/C/004844 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Cemiplimab
116
Cemiplimab-rwlc
23
Cemiplimab RWLC
17
Immunoglobulin G4
4
Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain)
3

Brand

Libtayo
71

Development codes

REGN2810
55
SDREGN2810
1
HDREGN2810
1

In one entry with another drug

Given together, or one or the other

cemiplimab+fianlimab
2

Studies by the year they started

129 studies that test it; most in 2026 (27); 6 more planned to start later

Studies that test cemiplimab, by start year
YearStudies
20101
20152
20163
20177
20189
20196
202012
20219
20225
202310
202415
202523
202627

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
39
Phase 2
101
Phase 3
11
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 42 · Other 93

Regeneron Pharmaceuticals (35) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (6) · H. Lee Moffitt Cancer Center and Research Institute (5) · National Cancer Institute (NCI) (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Columbia University (3) · Mayo Clinic (3)

Often tested with

Tested in the same studies.

Fianlimab (16) · Cetuximab (5) · Paclitaxel (4) · Gemcitabine (3) · Carboplatin (3) · Dupilumab (3) · Pembrolizumab (3) · Sarilumab (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 20, 2 in phase 3

Studies that test cemiplimab, phase 3 first.

Studies

Open first, then newest update. How each study uses cemiplimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 135

See all 135 studies that test cemiplimab →

Given beside what is tested · 68 — cemiplimab is usual care or a partner of the new treatment

Showing 20 of 68.

As the comparator · 2 — what is tested is compared with cemiplimab

Codes

What other systems call cemiplimab · ClinicalTrials.gg INT000975

  • MeSH (NLM) C000627974cemiplimabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 6QVL057INTCEMIPLIMABConfirmed FDA, NLM
  • RxNorm 2058826One source FDA
  • NCI Thesaurus C121540CemiplimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.